doi: 10.1161/01.RES.0000204572.65400.a5
© 2006 American Heart Association, Inc.
Editorials |
Spatio-Temporal Diversity of Apoptosis Within the Vascular Wall in Pulmonary Arterial Hypertension
Heterogeneous BMP Signaling May Have Therapeutic Implications
From the Pulmonary Hypertension Program, University of Alberta, Edmonton, Canada.
Correspondence to Evangelos D. Michelakis, MD, FACC, FAHA, Director, Pulmonary Hypertension Program, University of Alberta, Canada Research Chair in Pulmonary Hypertension, Edmonton, Alberta T6G2B7, Canada. E-mail emichela@cha.ab.ca
See related article, pages 209–217
Key Words: apoptosis • pulmonary circulation • pulmonary hypertension • vascular remodeling • survivin
An extract of the first 250 words of the full text is provided, because this article has no abstract. |
 |
Introduction |
|---|
"The temptation to form premature theories is the bane of our profession."— Sherlock Holmes
Although pulmonary arterial hypertension (PAH) was originally thought to be a disease of increased pulmonary arterial (PA) tone, we now know that vasoconstriction is important only in a minority of patients.1 PAH is characterized by increased proliferation of PA endothelial cells (PAECs) and PA smooth muscle cells (PASMCs), leading to narrowing or even obliteration of the PA lumen, increased pulmonary vascular resistance (PVR), right ventricular failure and premature death.1
Voelkel and Tuder suggested that the proliferative remodeling in the PAs resembles cancer.2 Several features, in addition to excessive proliferation, make this hypothesis attractive. For example, as in cancer, the development of PAH appears to result from a "multiple-hit" mechanism, where environmental factors (virus, inflammation, anorexigens, shunt-induced shear stress, etc) interact with a genetic predisposition (loss-of-function mutations in the bone morphogenetic protein receptor II, BMPR-II) culminating in disease.1 That PAH is characterized by a cancer-like apoptosis resistance is supported by recent reports that proapoptotic therapies can reverse PAH, similarly to cancer, where proapoptotic chemotherapies are the mainstay of treatment. Several experimental PAH treatments (including dichloroacetate,3 simvastatin,4 sildenafil,5 imatinib,6 anti-survivin,7 and K+ channel replacement gene therapies8) induce apoptosis of PASMCs, leading to reversal of vascular remodeling and PAH. In sharp contrast, strategies designed to promote survival and inhibit apoptosis of PAECs (cell-based gene transfer of angiopoietin-19 or eNOS,10 caspase inhibitors11) also improve PAH, particularly at early stages. These apparently conflicting reports can be rationalized by
Related Article:
Circ. Res. 2006 98: 209-217.
This article has been cited by other articles:
 |
|
 |
|
  S. L. Archer and E. D. Michelakis Phosphodiesterase Type 5 Inhibitors for Pulmonary Arterial Hypertension N. Engl. J. Med., November 5, 2009; 361(19): 1864 - 1871. [Full Text] [PDF]
|
|
|
|
 |
|
 H. C. Champion, E. D. Michelakis, and P. M. Hassoun Comprehensive Invasive and Noninvasive Approach to the Right Ventricle-Pulmonary Circulation Unit: State of the Art and Clinical and Research Implications Circulation, September 15, 2009; 120(11): 992 - 1007. [Full Text] [PDF]
|
|
|
|
|
|
G. Butrous, H. A. Ghofrani, and F. Grimminger Pulmonary Vascular Disease in the Developing World Circulation, October 21, 2008; 118(17): 1758 - 1766. [Full Text] [PDF]
|
|
|
|
|
|
E. D. Michelakis, M. R. Wilkins, and M. Rabinovitch Emerging Concepts and Translational Priorities in Pulmonary Arterial Hypertension Circulation, September 30, 2008; 118(14): 1486 - 1495. [Full Text] [PDF]
|
|
|
|
 |
|
 N. Homma, T. Nagaoka, V. Karoor, M. Imamura, L. Taraseviciene-Stewart, L. A. Walker, K. A. Fagan, I. F. McMurtry, and M. Oka Involvement of RhoA/Rho kinase signaling in protection against monocrotaline-induced pulmonary hypertension in pneumonectomized rats by dehydroepiandrosterone Am J Physiol Lung Cell Mol Physiol, July 1, 2008; 295(1): L71 - L78. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. McMurtry, S. Bonnet, E. D. Michelakis, S. Bonnet, A. Haromy, and S. L. Archer Statin therapy, alone or with rapamycin, does not reverse monocrotaline pulmonary arterial hypertension: the rapamcyin-atorvastatin-simvastatin study Am J Physiol Lung Cell Mol Physiol, October 1, 2007; 293(4): L933 - L940. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Bonnet, G. Rochefort, G. Sutendra, S. L. Archer, A. Haromy, L. Webster, K. Hashimoto, S. N. Bonnet, and E. D. Michelakis The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted PNAS, July 3, 2007; 104(27): 11418 - 11423. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Nagendran and E. Michelakis MRI: One-Stop Shop for the Comprehensive Assessment of Pulmonary Arterial Hypertension? Chest, July 1, 2007; 132(1): 2 - 5. [Full Text] [PDF]
|
|
|
|
|
|
P. B. Sehgal, S. Mukhopadhyay, F. Xu, K. Patel, and M. Shah Dysfunction of Golgi tethers, SNAREs, and SNAPs in monocrotaline-induced pulmonary hypertension Am J Physiol Lung Cell Mol Physiol, June 1, 2007; 292(6): L1526 - L1542. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. McMurtry, R. Moudgil, K. Hashimoto, S. Bonnet, E. D. Michelakis, and S. L. Archer Overexpression of human bone morphogenetic protein receptor 2 does not ameliorate monocrotaline pulmonary arterial hypertension Am J Physiol Lung Cell Mol Physiol, April 1, 2007; 292(4): L872 - L878. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. C. Aird Phenotypic Heterogeneity of the Endothelium: II. Representative Vascular Beds Circ. Res., February 2, 2007; 100(2): 174 - 190. [Abstract] [Full Text] [PDF]
|
|